Video on Utube https://youtu.be/fOa_2Bc-lfY

Preliminary Study: CBD May Help Battle Treatment-Resistant Epilepsy

Epilepsy is a common neurological disorder experienced by children, and approximately 20% of patients (around 93,200 children in the US, and around 153,000 children in Europe) are unable to control their seizures with commonly used medications. Due to the growing evidence that some cannabinoids found in cannabis may help to reduce neuron hyper-excitability, certain strains are being used to help treat epilepsy.

This is particularly true of cannabis strains with a high concentration of cannabidiol (CBD). In turn, pharmaceutical companies have been working on ways repeat this success with cannabis-based drugs.

GW Pharmaceuticals Releases Preliminary Data On Epidiolex

Epidiolex is a standardized, high-CBD cannabis drug produced by GW Pharmaceuticals, a company based in the United Kingdom. Preliminary data from a recent clinical trial on Epidiolex was released in June, and it shows evidence of the product’s probable efficacy for treatment-resistant convulsive and non-convulsive epilepsy (e.g. Dravet syndrome, Lennox-Gastaut syndrome) in children.

27 epilepsy patients (average age of 10.5 years; one participant was 26 years old), with Dravet syndrome as the most prevalent condition, were entered into the uncontrolled trial for 12 weeks at 2 different US hospitals under Investigational New Drug (IND) applications through the FDA. Epidiolex was used as an add-on therapy to the current treatment regimen of the participants -participants were each taking 2.7 other anti-epileptic drugs on average at the time of trial.